Belzutifan: a novel therapy for von Hippel–Lindau disease

A recent clinical trial reports promising efficacy and safety data for belzutifan in patients with von Hippel–Lindau (VHL) disease–associated renal cell carcinoma. On the basis of these results, belzutifan became the first therapeutic agent to be approved for the systemic treatment of cancer associa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Nephrology 2022-04, Vol.18 (4), p.205-206
Hauptverfasser:	Zhou, Jingcheng, Gong, Kan
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4028/67/1059/602 692/4028/67/589/1588/1351 Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Renal Cell - pathology Clinical trials Female Humans Immunotherapy Kidney cancer Kidney Neoplasms - pathology Kinases Male Medicine Medicine & Public Health Mutation Nephrology News & Views news-and-views Patients Proteins Quality of life Tumors Urology Vascular endothelial growth factor von Hippel-Lindau Disease - complications von Hippel-Lindau Disease - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A recent clinical trial reports promising efficacy and safety data for belzutifan in patients with von Hippel–Lindau (VHL) disease–associated renal cell carcinoma. On the basis of these results, belzutifan became the first therapeutic agent to be approved for the systemic treatment of cancer associated with VHL disease.
ISSN:	1759-5061 1759-507X
DOI:	10.1038/s41581-022-00544-5